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Abstract
Safe, effective adjuvants that enhance vaccine potency, including induction of neutralizing Abs against a broad range of
variant strains, is an important strategy for the development of seasonal influenza vaccines which can provide optimal
protection, even during seasons when available vaccines are not well matched to circulating viruses. We investigated the
safety and ability of Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE), a synthetic Toll-like receptor (TLR)4 agonist
formulation, to adjuvant FluzoneH in mice and non-human primates. The GLA-SE adjuvanted Fluzone vaccine caused no
adverse reactions, increased the induction of T helper type 1 (TH1)-biased cytokines such as IFNc, TNF and IL-2, and
broadened serological responses against drifted A/H1N1 and A/H3N2 influenza variants. These results suggest that
synthetic TLR4 adjuvants can enhance the magnitude and quality of protective immunity induced by influenza vaccines.
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Introduction
Seasonal influenza epidemics are responsible for an average
36,000 deaths and 226,000 hospitalizations annually in the United
States alone [1]. Worldwide 3–5 million cases of severe influenza
infection occur each year, resulting in between 250,000–500,000
deaths [2]. Although influenza infection rates are highest in
children, increased mortality occurs in those older than 65 years,
in children less than 2 years of age, and in patients with medical
conditions [2].
Vaccination is the best preventative measure against influenza,
and acts by increasing neutralizing Abs directed against the HA,
the major surface glycoprotein [3]. Currently licensed trivalent
seasonal influenza vaccines include antigens from two circulating
type A strains and one type B influenza strain. One limitation to
seasonal vaccine efficacy is that selected influenza strains are not
always representative of the circulating virus, and as a conse-
quence the resulting protection afforded by the vaccine may be
reduced [4]. Even for years in which components are antigenically
well matched to circulating influenza strains, vaccines are only 60–
80% effective at preventing death in older adults aged 65 years
and over and are only effective at preventing 70–90% of influenza-
specific illnesses in younger adults [2,4,5]. When the vaccine is
mismatched, efficacy against serologically confirmed influenza
illness in adults (18–64 years of age) can be as low as 50% [5]; in
those .65 years, efficacy is as low as 35%[4].
Adjuvants provide an important means of improving influenza
vaccines. To be effective, these adjuvants should increase the levels
of hemagglutination-inhibition (HI) Ab titers against the HA
components included in the vaccine and ideally also against
variant viruses possessing drifted HA proteins. Emulsion-based
adjuvants are currently used in certain licensed seasonal influenza
vaccines. MF59
TM (an oil-in-water adjuvant) combined with a
seasonal influenza vaccine, (FluadH, Novartis Vaccines and
Diagnostics) has been approved in some European countries since
the late 1990’s [6]. In addition, two H5N1 vaccines have recently
been approved in Europe: FocetriaH (MF59 + H5N1 vaccine;
Novartis), and Prepandrix
TM (an AS03+H5N1 vaccine; GlaxoS-
mithKline) [6]. The use of formulations containing oil-in-water
emulsions plus Toll-like receptor (TLR) agonists [7] have been
successfully used in combination with influenza vaccine and shown
to enhance humoral and cellular immunity in animal models
compared to using the vaccine alone.
The most advanced TLR4 agonist is an adjuvant derived from
the LPS of Salmonella minnesota which is known as Monophosphoryl
Lipid A (MPLH). MPLH in a variety of formulations has been
licensed in Europe as a component of the hepatitis B vaccine
FendrixH [8] and HPV vaccine CervarixH; both containing MPL/
alum. The inclusion of GSK’s AS04 Adjuvant System in
CervarixH, recently approved in the US, is believed to significantly
broaden immune responses against HPV serotypes not contained
in the vaccine.
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developed a series of formulations containing a synthetic molecule
called Glucopyranosyl Lipid A (GLA), which is optimized for
binding to the human MD2 molecule of the TLR4 complex. GLA
is active on mouse and human antigen presenting cells (APC) ([9];
Coler et al., manuscript submitted), resulting in the induction of
cytokines such as IL-12 and TNF.
Here we evaluate the safety and immunogenicity of GLA in a
stable-emulsion (GLA-SE) combined with seasonal influenza
vaccines in mice and cynomolgus monkeys. The results demon-
strate that the adjuvanted Fluzone vaccine had increased humoral
and cellular immunogenicity (characterized by a T-helper 1 (TH1)-
biased immune response). The GLA-SE adjuvanted vaccine
caused no adverse side effects in animals and enhanced the
potency of the Fluzone vaccine both in terms of Ab and T cell
responses and in broadened serological responses against drifted
A/H1N1 and an A/H3N2 influenza variant(s) compared to
vaccination with Fluzone alone.
Results
Safety and Reactogenicity af Fluzone+ GLA-SE
To address the safety of GLA-SE in NHPs, we observed the site
of injection for reactogenicity and examined several markers
indicative of systemic inflammatory responses. Safety and toxicity
data were collected during the course of non-human primate
(NHP) dose escalation studies examining the immunogenicity and
efficacy of Fluzone+GLA-SE. Two IM administrations of 1 to
50 mg of GLA-SE in combination with Fluzone over 30 days were
well tolerated by cynomolgus macaques (Table S1).
There was no evidence of injection site reactions or systemic
toxicity in the animals receiving the Fluzone+GLA-SE vaccine or
adjuvant alone. No definitive test-article-related changes in
hematology were identified. Serum chemistry changes were
limited to a mild display of a hepatic acute phase response (mild
increases in both CRP and circulating fibrinogen concentrations)
after each injection in groups injected with Fluzone+GLA-SE
(Table S1).
The Fluzone+GLA-SE Vaccine Increases and Broadens Hi
Ab Levels
We recently reported the immunological effects of combining
Fluzone with a research-grade GLA in an oil-in-water emulsion in
BALB/c mice [7]. To assess the ability of SE and GLA-SE to
enhance Ab activity against influenza strains when formulated
with the Fluzone vaccine, we first compared the serum HI titers
induced against A/H3N2 influenza variants following immuniza-
tion in mice. HI titers were measured against the vaccine strain A/
Wisconsin/67/2005(H3N2)(Wis/05) and three antigenic variants
which represent the A/H3N2 components of past seasonal
influenza vaccines: A/Brisbane/10/2007(H3N2), A/Wyoming/
02/2003(H3N2) and A/Panama/2007/99(H3N2) (Bris/07, Wyo/
03 and Pan/99, respectively). The phylogenetic relationship
among all of the A/H3N2 strains except Pan/99 has been
recently described [10].
In mice administered a single immunization, only Fluzone
formulated with GLA-SE significantly increased HI titers against
the vaccine and drifted A/H3N2 strains compared to immuniza-
tion with Fluzone alone [2 to 6.5-fold increase in titer (p,0.05);
Figure 1]. Furthermore, the group given Fluzone+GLA-SE
induced significantly higher HI Ab titers against the drifted
Bris/07 and Pan/99 strains compared to immunization with
Fluzone formulated with SE [(p,0.05); Figure 1]. Following a
vaccine boost, Fluzone+SE elicited significantly higher HI titers
against the vaccine strain (Wis/05; 16-fold increase in HI titer over
Fluzone alone) and the drifted H3N2 strains [(Bris/07,Wyo/03
and Pan/99); 16- and 14-, and 2.7-fold increase in HI titer over
Fluzone alone, respectively] [(p,0.05); Figure 1]). The addition of
GLA to Fluzone+SE further enhanced HI titers over those
achieved either by vaccine alone [21-fold, (p,0.05); Figure 1] or
by Fluzone+SE (Figure 1). Fold-increase in HI titers in mice
receiving Fluzone+GLA-SE were 47-, 35- and 10.7-fold higher
compared with titers elicited by Fluzone alone when tested against
the drifted Bris/07, Wyo/03, and Pan/99 strains, respectively
[(p,0.05); Figure 1B]. These data demonstrate that combining the
trivalent influenza vaccine with either SE or GLA-SE not only
enhances vaccine potency, but also induces broader Ab responses
against antigenically drifted influenza strains.
To examine the potential of SE and GLA-SE to induce cells
associated with long-lived humoral immunity, we enumerated
bone marrow plasma cells (BMPC) that secreted IgG specific for
the Wis/05, Bris/07 and Pan/99 influenza strains. When
compared to vaccination with Fluzone alone, both the Fluzo-
ne+SE and Fluzone+GLA-SE vaccines significantly enhanced
virus-specific BMPC levels against these A/H3N2 strains [,11-
fold for the vaccine strain Wis/05, (p,0.001); and ,16-fold for
the drifted Bris/07 strain, (p,0.01), shown in Figure 2A].
Although the Ab levels were lower than for Bris/07 and Wis/
05, Fluzone+GLA-SE also enhanced virus-specific BMPC levels
against the drifted Pan/99 strain about 10-fold [(p,0.01);
Figure 2A]. As expected from the serum IgG results, the GLA-
SE-adjuvanted Fluzone vaccine generated significantly more Wis/
05-specific BMPC than immunization with Fluzone+SE [,2 fold;
(p,0.01)]. These data indicate that formulating Fluzone with
GLA-SE induces a long-lasting humoral response against not only
the vaccine strain but also antigenically drifted influenza variants.
IFNc:IL-10 ratios were increased in in vitro-stimulated splenocytes
collected from mice immunized with GLA-SE and Fluzone
compared with those from mice administered Fluzone alone,
demonstrating a clear Th1-type immune response (Figure 2B).
Next, we examined whether results observed in mice could be
reproduced in a higher animal species. NHPs were immunized
with the 2007-08 Fluzone vaccine and geometric mean Ab titers
(GMT) against vaccine components [A/Solomon Islands/3/
2006(H1N1), A/Wisconsin/67/2005(H3N2), and B/Malaysia/
2506/2004] and antigenically drifted strains [A/Brisbane/59/
2007(H1N1), A/New Caledonia/20/1999(H1N1), A/Beijing/
262/1995(H1N1) and A/Uruguay/716/2007(H3N2)] were mea-
sured.
In human clinical studies, the criteria commonly used to assess
vaccine immunogenicity include a) rates of seroconversion (a four-
fold or greater increase in post-vaccination HI titer compared with
pre-vaccination titer) or b) rates of achievement of an HI titer of
$40. An HI titer of $40 is a serologic endpoint generally
considered to be associated with at least a 50% reduction in the
risk of infection or disease within a population [11]. In this study we
measured serum HI titers four weeks after both the prime and boost
immunizations. Following a single immunization, the Fluzone
vaccine induced HI titers of $40 against all 3 components of the
vaccine in only 1 of 3 animals (Table S2). The addition of emulsion
to the Fluzone vaccine resulted in titers of $40 against A/H1N1/
Solomon Islands, A/H3N2/Wisconsin, and B/Malaysia compo-
nents in 2 of 3, 3 of 3, and 1 of 3 animals, respectively. Formulation
of Fluzone with GLA-SE (at 25 mg) resulted in titers of $40 to the
type A components of the vaccine in all 3 animals and against B/
Malaysia virus in 2 of 3 animals (Table S2). After the boost, all
animals achieved titers of $40 titers against all three vaccine
components with either Fluzone+SE vaccine or Fluzone+GLA-SE
Flu Vaccine Plus GLA-SE
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alone group achieved titers of =40 against the A/H1N1 and B/
Malaysia components; these results differ from the stronger
responses detected against the A/H3N2 component (Table S2).
I nc o n t r a s tt ot h eo b s e r v a t i o n sm a d ei nm i c e ,t h es e r u mH IA b
titers of NHP following one (day 30) or two immunizations (day 58)
with Fluzone+SE were not significantly different compared to the
group administered the Fluzone vaccine alone (Figure 3). Neverthe-
Figure 1. GLA-SE enhances HI titers to the A/H3N2 vaccine component and antigenically drifted A/H3N2 influenza strains. Balb/c
mice were immunized with Fluzone (2006–2007) either alone ( - ), or formulated with emulsion (SE), or glucopyranosyl-lipid-adjuvant (GLA-SE). (A)
Serum HI titers one week after the prime and boost (N=7 mice/group). Shown are the individual mouse HI titers (diamonds) and the geometric mean
titer (GMT) (indicated by the horizontal bars6the 95% CI) against the vaccine strain (Wis/05) and the antigenically drifted H3N2 strains. The assay
detection limit was set at #10. Statistical significance between groups was determined and compared to Fluzone (*p,0.05) or Fluzone+SE
(**p,0.05). (B) The fold-increase in mean HI titer over that seen with Fluzone is shown for Fluzone+SE or Fluzone+GLA-SE one week after the prime
and boost immunizations.
doi:10.1371/journal.pone.0013677.g001
Flu Vaccine Plus GLA-SE
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vaccine formulations enhanced HI titers in a GLA-SE dose
dependent manner. HI titers were increased by, on average, 2–28
fold compared with titers achieved in vaccine groups lacking GLA-
SE. After the first immunization, Fluzone formulated with GLA-SE
at 5–50 mg doses elicited higher mean serum HI titers to the A/
H1N1/Solomon Islands and A/H3N2/Wisconsin components of
the vaccine compared with titers elicited by Fluzone alone. Following
the boost, animals that received Fluzone+SE, and Fluzone plus GLA-
SE, showed a dose-dependent enhancement in the mean serum HI
titers to all three components of the vaccine (Figure 3).
A desirable feature of an adjuvanted seasonal influenza vaccine
is the ability to induce more broadly cross-reactive Abs against
antigenically drifted variants or homosubtypic heterovariant
influenza strains that are not included in the vaccine for a given
season [12]. To address the ability of SE and GLA-SE to enhance
NHP Ab responses against antigenically drifted influenza viruses
when formulated with the Fluzone vaccine, we compared the HI
Figure 2. GLA-SE enhances IgG-secreting BMPCs to vaccine and drifted A/H3N2 strains and induces cross-reactive type-1 immunity.
Mice were immunized Fluzone (2006–2007) either alone ( - ), or formulated with emulsion (SE), or GLA-SE. (A) Shown are virus-specific [vaccine (Wis/
05) or drifted H3N2 strains] IgG-secreting BMPC responses five weeks after boost from individual mice (diamonds; N=4/group). The group mean is
represented by the horizontal bar 6 standard deviation (s.d.) per million cells. Statistical significance was determined and compared to Fluzone
(*p,0.05) or Fluzone+SE (**p,0.05). (B) IFNc:IL-10 ratios from immunized mice (N=4/group) seven weeks after the boost immunization. Splenocytes
were harvested and cultured with 5 HAU of inactivated Wis/05, Bris/07, Wyo/03 or Pan/99 influenza virus strains for 3 days. Supernatants were
analyzed by ELISA. Results represent the mean IFNc:IL-10 ratio.
doi:10.1371/journal.pone.0013677.g002
Flu Vaccine Plus GLA-SE
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variants following experimental vaccination.
NHP that were primed and boosted with escalating doses of
Fluzone+GLA-SE exhibited higher HI titers not only against the
vaccine strain but also to the most recent drifted influenza variant
(A/H1N1/Brisbane), a component of the subsequent years
vaccine formulation (Figure 4). HI responses against H1N1 strains
included in vaccine formulations from 1998 to 2006 were also
examined. Vaccination with Fluzone alone did not elicit responses
against these strains. However, when Fluzone was administered
with 5–50 mg GLA-SE, robust HI titers were achieved (Figure 4)
following a boost immunization (cross-reactive titers reached levels
Figure 3. GLA-SE enhances serum HI titers to the A/H1N1 and A/H3N2 components in Fluzone. NHPs (N=3/group) were injected with
saline (-), or were immunized with Fluzone (2007–2008) alone (+), or Fluzone formulated with emulsion (SE), or GLA-SE (1, 5, 25 or 50 mg). Serum
samples were collected 4 weeks after the prime and boost immunizations, at day 30 or day 58, respectively. Shown are the HI titers from individual
animals (diamonds) and GMT (indicated by the horizontal bars 6 the 95% CI) against the three components of the Fluzone vaccine.
doi:10.1371/journal.pone.0013677.g003
Flu Vaccine Plus GLA-SE
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strains). Titers to the A/H1N1/Beijing strain were also higher in
the groups given GLA-SE (5–50 mg) than titers observed with
Fluzone, either used alone or combined with SE or the lowest dose
of GLA-SE (1 mg), although most of the animals did not achieve
titers $40 (Figure 4, Table S3).
In addition to testing HI responses to drifted H1N1 strains,
,HI titers were measured against the vaccine strain (A/H3N2/
Wisconsin) (Figure 3) and one antigenically drifted A/H3N2
strain included in seasonal influenza vaccines in 2008 (A/
H3N2/Uruguay) (Figure 4). Although Fluzone+SE stimulated
higher HI titers to the vaccine strain than Fluzone alone,a boost
was required to induce the higher titers to the drifted A/
H3N2/Uruguay strain (Figure 4). All of the NHPs that received
Fluzone+GLA-SE (5–50 mg) exhibited cross-reactive HI titers
well above 40 against the drifted H3N2 strain following two
immunizations, and 2 of 3 NHPs given the lowest dose GLA-SE
(1 mg) achieved this titer. In contrast, only 1 of 3 NHPs
reached a cross reactive titer $40 following immunization
with Fluzone+SE, and none of the animals given Fluzone
without adjuvant responded to the drifted strain (Figure 4,
Table S3).
Cytokine Response in Immunized Animals
Cellular immune responses, including TH1-type responses, play
a critical role in the clearance of influenza viruses in animal models
and are associated with protection against influenza-related illness
in the elderly. We, therefore, assessed the ability of the GLA-SE-
and SE-formulated Fluzone vaccines to elicit influenza-specific
cellular responses. In initial studies, spleen cells from mice
immunized with Fluzone alone or with either SE or GLA-SE
were restimulated in vitro with the vaccine strain or with the
antigenically drifted A/H3N2 influenza The levels of cytokine
produced in response to stimulation by any A/H3N2 strain were
comparable, suggesting that the cellular responses are most likely
directed towards conserved proteins within the antigen mixture
(Figure S1 (7)). Fluzone+GLA-SE vaccinated mice induced
significantly greater levels of antigen-specific IFNc compared to
responses from mice immunized with Fluzone+SE or Fluzone
alone (Figure S1 (7)). In sharp contrast to GLA-SE, the vaccine
Figure 4. GLA-SE enhances serum HI titers to antigenically drifted A/H1N1 and A/H3N2 influenza strains following a boost
immunization. NHPs (N=3/group) were immunized with Fluzone (2007–2008) alone, or formulated with emulsion (SE), or GLA-SE (1, 5, 25 or
50 mg). Serum samples were collected 4 weeks after the boost (day 58). Shown are the HI titers from individual animals (diamonds) and the GMT
(indicated by the horizontal bars 6 the 95% CI) against the antigenically A/Brisbane/59/2007(H1N1), A/New Caledonia/20/99(H1N1) and A/Beijing/
262/1995(H1N1) strains and the drifted A/Uruguay/716/2007(H3N2) strain.
doi:10.1371/journal.pone.0013677.g004
Flu Vaccine Plus GLA-SE
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13677formulated with SE induced a strong virus-specific TH2 cytokine
response characterized by significantly greater levels of IL-5
compared to Fluzone alone or Fluzone+GLA-SE (Figure S1 (7)).
Greater levels of IL-10 were induced in response to the vaccine
with SE compared to GLA-SE (Figure S1 (7)). Comparison of
IFNc to IL-10 levels, measured after the second immunization as
shown in Figure 2B, shows that GLA-SE directs type-1 cellular
responses, characterized by the production of IFNc. These data
suggest that the virus-specific recall responses can be modulated by
formulating Fluzone; inclusion of an oil-in-water emulsion induces
aT H2 response whereas the addition of a TLR4 agonist to the
emulsion directs a TH1 response.
In additional studies we used whole blood assays (WBA) to
assess antigen-specific cytokine responses of immunized and non-
immunized monkeys (Figure 5A). To evaluate T cell responsive-
ness to the H1N1 and H3N2 components of the Fluzone vaccine,
the levels of IFNc, TNF, IL-2, IL-6, IL-5 and IL-4 secreted during
WBA were evaluated by a TH1/TH2 Cytokine Bead Array. All of
the NHPs immunized with any of the Fluzone+GLA-SE (5-25 mg)
vaccines produced increased H1N1- and H3N2-specific IFNc
responses four weeks after the second immunization compared to
NHPs that were immunized with the Fluzone alone, Fluzone with
SE, or Fluzone with 1 mg GLA-SE (Figure 5A). All animals that
received the booster immunizations with Fluzone+GLA-SE at 25
Figure 5. Cellular responses after injection with saline, Fluzone alone, or combined with SE or GLA-SE. NHP (N=3/group) were given 2
injections, 4 weeks apart with saline, Fluzone, Fluzone+SE or Fluzone+GLA-SE (1, 5, 25 and 50 mg). (A) IFNc, IL-2, TNF and IL-5 (pg/mL) recall responses
after stimulation of whole blood with H1N1 or H3N2 were evaluated by CBA at day 0 and day 58. (B) IFNc:IL-5 ratios of cytokine recall responses after
stimulation of whole blood with H1N1 or H3N2, were evaluated by CBA at day 58. (C) Granzyme B levels (pg/mL) responses in whole blood following
stimulation with H1N1 or H3N2 was evaluated by Luminex at day 58. Horizontal lines represent median Granzyme B concentrations. (D) Chemokine
responses to Fluzone antigens after immunization. MCP-3 and IP-10 (pg/mL) responses in whole blood following stimulation with H1N1 or H3N2
were evaluated by Luminex at day 58. Horizontal lines represent median chemokine concentrations.
doi:10.1371/journal.pone.0013677.g005
Flu Vaccine Plus GLA-SE
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13677and 50 mg also had increased IL-2 and TNF levels compared to
those receiving Fluzone alone, Fluzone+SE, or Fluzone+GLA-SE
(1 or 5 mg) boosts (Figure 5A). Thus, only animals receiving the
Fluzone+GLA-SE at the highest doses (25 or 50 mg GLA)
produced elevated levels of all three of the TH1-associated
cytokines IFNc, TNF and IL-2. The cytokine responses 4 weeks
post-boost (day 58) revealed that NHP boosted with Fluzone alone
and Fluzone+SE had specific H1N1 and H3N2 responses marked
by lower TH1:TH2 cytokine ratios than those immunized with
Fluzone+GLA-SE at 5, 25 and 50 mg (Figure 5B). The highest
IFNc:IL-5 ratios (.100) produced in response to both the H3N2
and H1N1 components of the Fluzone vaccine were observed in
animals immunized with Fluzone +25 mg of GLA-SE. Interest-
ingly, the addition of GLA-SE to the Fluzone vaccine increased
median levels of H1N1- and H3N2-specific Granzyme B
(Figure 5C), as well as several chemokines. These chemokines
[(C-X-C motif) ligand 10 (CXCL10), also called IP-10) and
monocyte-chemotactic-protein-3 (MCP-3; also called chemokine
(C-C motif) ligand 7 (CCL7)] are selectively expressed on
monocytes, endothelial cells, and fibroblasts, and all are
chemotactic for and activate a great variety of inflammatory cell
types including monocytes/macrophages, T cells, NK cells, and/
or dendritic cells (Figure 5D).
Discussion
Next generation influenza vaccines that potentiate immune
responses and elicit protection against a broader range of
antigenically drifted strains are urgently needed. To further
advance development of such vaccines, we have analyzed the
impact on immune responses of incorporating a stable oil-in-water
emulsion and a synthetic TLR4 agonist into a standard influenza
vaccine. The experiments described in this report are the first to
evaluate an oil-in-water emulsion (SE) with various concentrations
of this synthetic TLR4 agonist (GLA), all in combination with
Fluzone, a licensed trivalent inactivated influenza vaccine for its
safety and ability to significantly enhance immune responses in
both mice and NHP. With the ever increasing need for safe ways
to either improve vaccine efficacy and/or to provide dose sparing
effects, most candidate adjuvants fail to reach the market place
because of safety issues including toxicity or reactogenicity
particularly at the site of injection. Though increased levels of
pro-inflammatory cytokines were observed in the context of GLA-
SE, there was no evidence of injection site reactions or systemic
toxicity in the animals receiving the Fluzone+GLA-SE vaccine or
adjuvant alone.
Our results demonstrate that incorporating SE into Fluzone
enhances Ab responses. Furthermore, the incorporation of GLA
with SE enhances the same Ab responses, stimulates production of
Abs that cross-react with antigenically variant influenza strains not
present in the vaccine, and generates TH1 cellular immune
responses. Thus, our studies clearly demonstrate that GLA-SE
provides further enhancement and broadening of the immune
responses already elevated by the addition of SE to Fluzone.
The ability of SE to adjuvant flu vaccines, as observed in our
studies, isingeneralagreement withthosepreviously reported for
another oil-in-water adjuvant, MF59
TM [13,14]. After two
immunizations, the addition of SE to the Fluzone vaccine
increased HI titers to the A/H1N1/Solomon Islands and the A/
H3N2/Wisconsin components of the Fluzone vaccine to
seroprotective levels HI titers of $40. In contrast to previous
reports indicating the generation of cross-reactive Abs against
heterovariant influenza strains by the addition of oil-in-water
adjuvants [14], our results failed to demonstrate that the addition
of SE alone to Fluzone could increase HI titers against
antigenically drifted influenza variants. It should be noted that
we used a low dose of Fluzone vaccine and that even when
administered with SE, this may not be a potent enough
combination to stimulate cross-reactive antigen-specific respons-
es. Regardless, our results confirm those of others which indicate
that incorporation of SE in influenza vaccines is an important
step in the development of more effective seasonal and pandemic
influenza vaccines.
Our results clearly demonstrate that, compared to vaccination
with Fluzone alone or Fluzone formulated with SE, the further
addition of GLA increases cross-protective HI Ab responses
against antigenic variants. In this study, a single administration of
Fluzone with GLA-SE leads to the generation of HI titers at
seroprotective levels in a majority of NHP. GLA-SE further
enhanced HI titers in NHP following two immunizations, as
compared to either SE plus Fluzone or Fluzone alone. Previous
studies have shown that other TLR agonists, such as the TLR9
agonist CpG, enhance cellular interactions within germinal
centers, leading to the selection of B cells with a high affinity for
antigen binding [15]. GLA-SE broadened HI responses and
generated more virus-specific BMPCs, the hallmark of long-term
humoral immunity [16], compared with SE alone. Taken
together, these results suggest that a GLA-SE-adjuvanted influenza
vaccine may elicit not only more durable but also more broadly
reactive Abs that have the potential to extend the protective
lifespan of the vaccine.
Our results also show that the addition of GLA-SE to the
Fluzone vaccine selectively shifts the cellular immune response
toward a type-1 cellular immune response pattern, characterized
by the production of IFNc. TLR4 agonists, such as MPL, have
been shown to be potent adjuvants in a range of species, including
humans [8,17]. NHP immunized with GLA-SE-adjuvanted
Fluzone vaccine produced higher Ab titers and type-1 cytokine
levels than those found in animals immunized with Fluzone alone
or a Fluzone+SE formulation. As many aging individuals
experience a shift from TH1t oT H2 responses [3] and a
concomitant increase in susceptibility to influenza disease, a
potent anti-influenza cellular response may be of particular
importance in older adults. Many elderly patients respond poorly
to the existing influenza vaccines [18,19]. The ability of the GLA-
SE adjuvant to induce potent type-1 cellular immune responses is
in marked contrast to the TH2 response induced by traditional
adjuvants such as Alum and MF59
TM [20]. The anti-viral activity
of type-1 cytokines such IFNc and TNF [21,22,23], and the
synergistic effect of these cytokines, against human influenza
viruses is well known [24]. The enhanced induction of both IFNc
and TNF by Fluzone adjuvanted with GLA-SE could positively
impact an influenza vaccination program aimed at the elderly
population since prior studies have reported a putative correlation
of cell mediated immunity and protection against influenza.
The weakened immune system of elderly people presents
particular challenges in the development of vaccines and adjuvants
for this population. There are well recognized changes in the
function of APCs, T cells and B cells in older people. Several
strategies to improve vaccination in the elderly have been
explored. A number of studies have shown that the use of
adjuvants (e.g. emulsions and TLR agonists) could trigger more
potent activation of APCs. Like other TLR4 containing adjuvants,
we have preliminary data demonstrating that GLA can induce
robust immune responses in aged mice and humans whose
immune systems have undergone significant decline with increas-
ing age. Recent studies suggest that T cell responses, rather than
Ab, may be a better immune correlate of protection against
Flu Vaccine Plus GLA-SE
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impaired TH1 responses [3,19].
The GLA-SE-adjuvanted Fluzone vaccine described in this
study elicits high IFNc:IL-10 and IFNc:IL-5 ratios that clearly
show a dominant type-1 cellular immune response. Potent virus-
specific IFNc responses are also thought to be capable of reversing
the age-related impairments of CTL activity considered essential
for viral clearance [25]. Therefore, the robust type-1 cellular
immune response elicited by GLA-SE may have implications for
the development of influenza vaccines better suited for the elderly.
Conversely, the oil-in-water-based adjuvant we evaluated clearly
shifted responses towards a type-2 cellular immune response,
dominated by IL-5 (and IL-10), results consistent with other
studies evaluating oil-in-water-based adjuvants, including
MF59
TM [26]. We show that, in the absence of the TLR4 agonist,
the oil-in-water emulsion adjuvant potentiates TH2 responses
reported to adversely affect viral clearance in animal models [27].
Thus, the data described herein suggests that influenza vaccines
combined with GLA-SE could provide an additional benefit to the
oil-in-water emulsion adjuvants by generating more broadly cross-
reactive Ab responses, and by potentiation of TH1 responses.
Materials and Methods
Animals
Female BALB/c mice 6–7 weeks (Charles River Laboratories,
Wilmington, MA) were maintained under SPF conditions by IDRI
Animal Care and Use Committee (IACUC).
Twenty-one confirmed healthy male Cynomologus macaques
ages 4.7 to 6.6 years old and weights of 4.81 to 6.47 kg were
housed at SNBL USA (Everett, WA) in accordance with SNBL
USA’s IACUC. Monkeys were pre-screened for their influenza
status, randomized by body weights and assigned into study
groups.
Immunizations
The 2006–2007 Fluzone influenza vaccine formulated for the
Northern Hemisphere (Sanofi Pasteur, Swiftwater, PA), containing
antigens from A/New Caledonia/20/99(H1N1), A/Wisconsin/
67/2005(H3N2) and B/Malaysia/2506/2004 was used for the
murine studies. The 2007–2008 Northern Hemisphere Fluzone
influenza vaccine containing antigens from A/Solomon Islands/
3/2006(H1N1), A/Wisconsin/67/2005(H3N2) and B/Malaysia/
2506/2004, was used for the NHP studies. Fluzone was combined
with either IDRI’s oil-in-water emulsion (SE) or SE containing a
synthetic TLR4 agonist (GLA-SE), before administration to
animals. Adjuvant formulations were prepared as previously
described [28].
Mice were immunized IM twice, 3 weeks apart. Mice received a
low dose (0.2 mg total HA) of the 2006–2007 Fluzone vaccine with
or without SE, or GLA-SE (20 mg).
NHP (N=3/group) were immunized by IM injection on days 1
and 30 with the pediatric dose, which included 7.5 mg HA/strain
resulting in a total HA dose of 22.5 mg, of the 2007–2008 Fluzone
vaccine alone, or adjuvanted with SE, or escalating doses (1, 5, 25,
or 50 mg) of GLA-SE.
Influenza Strains and Proteins used for murine HI and
cytokine assays
To evaluate the ability of thev a c c i n e st oi n d u c es e r u mA b
responses against heterovariant influenza strains, vaccine and
non-vaccine drifted influenza A strains were selected for
use in HI assays and splenocyte cultures. A/Wisconsin/67/
2005(H3N2)(Wis/05), A/Wyoming/03/2003(H3N2)(Wyo/03)
and A/Panama/2007/99(H3N2)(Pan/99) strains were provid-
ed by the CDC and Prevention (Atlanta, GA) and purified viral
protein from A/Brisbane/10/2007(H3N2)(Bris/07) was pur-
chased from ProSpec (Rehovot, Israel). All of the viruses used
were grown in the allantoic cavity of embryonated eggs and
were stored at 280uCu n t i lu s e .
Clinical Assessments of NHP
Injection sites were evaluated prior to each inoculation, at
2 hours 630 minutes and again at 24, 48, 72, 96, 120 and
14461 hour after each dose, using a Draize dermal irritation
scoring system [29]. Clinical observations to establish the general
safety of vaccine administration were collected throughout the
investigation. Limb use impairment and food consumption were
evaluated for each monkey. The following parameters were also
measured: (1) body weight (weekly throughout the study), (2) rectal
temperature (at intervals prior to and following each dose, and at
6, 12 and 24 hours630 minutes after each dose), (3) urinalysis, (4)
hematological parameters, (5) coagulation, and (6) serum chem-
istry (shown in Table S1)). Blood samples were collected 5 days
before, on the day of, and 2, 30 and 58 days after the initial
inoculation. Serum was stored at 260uC until analysis.
Influenza strains used for NHP HI assays
For the NHP HI assays, the 2007 vaccine components,
including A/Solomon Islands/3/2006(H1N1), A/Wisconsin/67/
2005(H3N2) and B/Malaysia/2506/2004 plus all drifted A
(H1N1) strains incorporated in seasonal influenza vaccines since
1998 including A/Brisbane/59/2007(H1N1), A/New Caledonia/
20/99(H1N1) and A/Beijing/262/1995(H1N1) and the drifted
A/Uruguay/716/2007(H3N2) influenza strains were evaluated.
All viruses were provided by the Centers for Disease Control and
Prevention (Atlanta, GA).
Bone Marrow ELISPOT
Antigen-specific mouse bone marrow plasma cells were
quantified by ELISPOT as previously described, five weeks
after the second immunization (7). Purified and concentrated
A/Wisconsin/67/2005(H3N2)(Wis/05), A/Brisbane/10/2007
(H3N2)(Bris/07) and A/Panama/2007/99(H3N2)(Pan/99)
viral antigens were purchased from ProSpec for use in the
ELISPOT.
Cellular Immune Responses
Seven weeks after the second immunization, mice were
euthanized and spleens (N=4/group) were harvested. Spleno-
cytes were cultured with 5 HAU of inactivated A/Wisconsin/67/
2005(H3N2)(Wis/05), A/Brisbane/10/2007(H3N2)(Bris/07),
A/Wyoming/03/2003(H3N2)(Wyo/03) or A/Panama/2007/
99(H3N2)(Pan/99) influenza virus at 37uCi n5 %C O 2f o r
72 hrs following a method adapted from Lu et al [30]. Culture
supernatants were then collected and cytokine levels were
measured by ELISA according to the manufacturer’s instructions
(IFNa ˜ and IL-10, eBioscience, San Diego, CA).
Monkeys were bled at day 0 and 58 to evaluate cellular immune
responses by whole blood assay (WBA). Heparinized blood
(450 mL) was dispensed into 48-well plates (ICN Biomedicals,
Inc). Phytohemagglutinin (PHA; 100 mg/mL), Fluzone (9 mg/mL),
purified rH3 from A/Wisconsin/67/2005(H3N2) (10 mg/mL)
(Protein Sciences Corp., Meriden, CT), inactivated A/Solomon
Islands/3/2006(H1N1) virus (10HAU/mL) (provided by the
Centers for Disease Control and Prevention) or saline was then
added to provide stimulation in a final volume of 500 mL/well in
Flu Vaccine Plus GLA-SE
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200 mL plasma was collected and IFNc,? TNF, IL-2, IL-6, IL-5,
IL-4, Granzyme B, MCP3 and IP-10 levels measured using a
TH1/TH2 cytometric bead array (CBA) kit (Becton Dickinson) or
a custom Luminex panel (Panomics).
HI Assay
Sera were collected from mice one week after each immuniza-
tion. Anti-HI Abs specific to the A/H3N2 component of the
2006–2007 Northern Hemisphere Fluzone formulation, A/
Wisconsin/67/2005(H3N2)(Wis/05), and to the A/H3N2 com-
ponent of other seasonal influenza vaccines used since 2001
including A/Brisbane/10/2007(H3N2)(Bris/07), A/Wyoming/
03/2003(H3N2)(Wyo/03) or A/Panama/2007/99(H3N2)(Pan/
99) were determined as previously described using 0.5% turkey
RBC [31]. Mouse sera were treated with receptor destroying
enzyme followed by heat treatment (56uC, 30 min) before use in
the HI assay. The HI titer was defined as the reciprocal of the
highest dilution of sera which completely inhibits the agglutination
of the turkey RBCs.
Sera were collected from NHP on Day 1, 30 and 58 and
evaluated for the presence of hemagglutination inhibiting
antibodies specific to the 2007–2008 Northern Hemisphere
Fluzone components including A/Solomon Islands/3/
2006(H1N1), A/Wisconsin/67/2005(H3N2) and B/Malaysia/
2506/2004 and also against drifted A (H1N1) strains incorporated
in seasonal influenza vaccines since 1998 including A/Brisbane/
59/2007(H1N1), A/New Caledonia/20/99(H1N1) and A/Beij-
ing/262/1995(H1N1) and the drifted A/Uruguay/716/
2007(H3N2) influenza strain by means of established methods,
using four hemaglutinating units (HAU) of virus and 0.5% turkey
RBCs). NHP sera were treated with receptor destroying enzyme
followed by heat treatment (56uC, 30 min) before use in the HI
assay. Three separate HI assays were conducted on each serum
sample and each individual serum sample was assayed in duplicate
in each assay. The seroprotective rate was defined as the
percentage of animals per vaccine group that achieved a post-
vaccination HI titer of $ 40 HI. Preimmune titers in all animals
were #10.
Statistical Analysis
Statistical analysis was performed by a standard one-way
ANOVA with the Tukey Multiple Comparison Test between
the groups using GraphPad Prism (GraphPad Software, San
Diego, CA).
Supporting Information
Figure S1 Virus-specific cytokine responses 7 weeks post boost
with the 2006-2007 Fluzone influenza vaccine alone (-) or
formulated with either an oil and water emulsion (SE) or a
synthetic TLR4 agonist formulation (GLA-SE). Splenocytes were
harvested from 4 mice/vaccine group and cultured with 5 HAU of
inactived Wis/05, Bris/07, Wyo/03 or Pan/99 influenza strains.
Supernatants were collected 72 hours post culture and analyzed by
ELISA. Values represent the average virus-specific cytokine
responses detected in cultures +SD. One asterisk represents
significantly greater responses to Fluzone alone (p,0.05). Two
asterisks represents significantly greater responses to Fluzone+SE
(p,0.05). Three asterisks represents significantly greater responses
to Fluzone +GLA-SE (p,0.05).
Found at: doi:10.1371/journal.pone.0013677.s001 (0.06 MB
PDF)
Table S1
Found at: doi:10.1371/journal.pone.0013677.s002 (0.05 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0013677.s003 (0.04 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0013677.s004 (0.04 MB
DOC)
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